Dr. Archie Tse is currently the Executive Director in Oncology Early Development at Merck. He oversees the early clinical development of a number of novel agents in the immune-oncology pipeline, spanning various mechanisms of action and modalities. Prior to joining Merck, Dr. Tse was at Daiichi-Sankyo, where he assumed increasing responsibility in oncology Phase 1-3 drug development, most recently as the leader of the Oncology Team of Excellence for Strategy in Therapeutic Area, responsible for the development and implementation of the overall therapeutic area strategy. He also represented Daiichi-Sankyo on the Cancer Steering Committee of the FNIH Biomarker Consortium.
Dr. Tse is a board-certified medical oncologist who trained at the Memorial Sloan-Kettering Cancer Center, where he was an Assistant Member, with a research focus on preclinical and early clinical development of new anti-cancer therapeutics, including modulators of DNA damage response and the cell-cycle.
Dr. Tse obtained his MD. and PhD in Biochemistry & Molecular Biology from the University of Southern California, Los Angeles, California, US.